中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

72 records (took 0.029 seconds)

    신규한 패니바실러스 속 엠비티213 균주, 이를 이용한 발효인삼 및 이를 이용한 발효인삼 추출물을 함유하는 아토피 피부염의 예방 또는 치료용 조성물
    64.
    发明授权
    신규한 패니바실러스 속 엠비티213 균주, 이를 이용한 발효인삼 및 이를 이용한 발효인삼 추출물을 함유하는 아토피 피부염의 예방 또는 치료용 조성물 有权
    新款PAENIBACILLUS SP。 MBT213，使用其的发明金山和包含用于预防或治疗原生质体的发酵金山提取物的组合物

    公开(公告)号：KR101345226B1

    公开(公告)日：2013-12-26

    申请号：KR1020130090695

    申请日：2013-07-31

    Applicant: 충남대학교산학협력단

    Inventor： 송규용 ,  남명수 ,  김승형

    IPC: C12N1/20 ,  A23L19/00 ,  A23L33/00 ,  A61K36/258

    Abstract: The present invention relates to novel Paenibacillussp. MBT213 (microorganism deposition number KACC91831P) and to a fermented ginseng using the same. In addition, the present invention relates to a composition for preventing or treating atopic dermatitis which comprises extracts of fermented ginseng using Paenibacillussp. MBT213. A culture media of the Paenibacillussp. MBT213 (microorganism deposition number KACC91831P) has excellent effects which converts ginsenoside Rg1 inside the ginseng into Rd. In addition, the fermented ginseng or extract of the same which is manufactured by using the effects suppresses activities of MIP-1α (macrophage inflammatory protein-1α), IL-4 (interleukin-4) and IL-13 (interleukin-13) in order to be used as a medicine for treating or alleviating symptoms of various skin diseases such as atopic dermatitis.

    Abstract translation: 本发明涉及新型Paenibacillussp。 MBT213（微生物保藏号KACC91831P）和使用其的发酵人参。 此外，本发明涉及一种用于预防或治疗特应性皮炎的组合物，其包含使用Paenibacillussp的发酵人参提取物。 MBT213。 Paenibacillussp的文化媒体。 MBT213（微生物保藏号KACC91831P）具有将人参中人参皂苷Rg1转化为Rd的优异效果。 此外，通过使用该效果制造的发酵人参或其提取物抑制MIP-1α（巨噬细胞炎症蛋白-1α），IL-4（白细胞介素-4）和IL-13（白细胞介素-13）的活性 用作治疗或减轻诸如特应性皮炎等各种皮肤病症状的药物。

    뮤라야폴린 에이 유도체를 유효성분으로 함유하는 혈관 질환의 치료 또는 예방용 조성물
    65.
    发明公开
    뮤라야폴린 에이 유도체를 유효성분으로 함유하는 혈관 질환의 치료 또는 예방용 조성물 有权
    包含MURRAYAFOLINE用于治疗或预防血管疾病的衍生物的组合物

    公开(公告)号：KR1020130026081A

    公开(公告)日：2013-03-13

    申请号：KR1020110089469

    申请日：2011-09-05

    Applicant: 충남대학교산학협력단

    Inventor： 송규용 ,  명창선 ,  김영호

    IPC: A61K31/403 ,  A61P9/12 ,  A61P9/10 ,  A61P9/00

    CPC classification number: A61K31/404 ,  Y10S514/822 ,  Y10S514/824

    Abstract: PURPOSE: A composition containing a murrayafoline A derivative is provided to suppress platelet aggregation, and to prevent or treat vascular diseases. CONSTITUTION: A composition for preventing or treating vascular diseases contains a compound of chemical formula 1. In chemical formula 1, R1 is independently selected among hydrogen, C1-C6 alkyl, formyl, C1-C6 alkylester, and carboxylic acid; R2 is independently selected among hydrogen, hydroxy, C1-C6 alkyl, or C1-C6 alkyloxy; and R4 is independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 alkylketone.

    Abstract translation: 目的：提供含有药物衍生物衍生物的组合物，以抑制血小板聚集，并预防或治疗血管疾病。 构成：用于预防或治疗血管疾病的组合物含有化学式1的化合物。在化学式1中，R 1独立地选自氢，C 1 -C 6烷基，甲酰基，C 1 -C 6烷基酯和羧酸; R2独立地选自氢，羟基，C1-C6烷基或C1-C6烷氧基; 和R 4独立地选自氢，C 1 -C 6烷基，C 2 -C 6烯基或C 1 -C 6烷基酮。

    스네일―ｐ５３ 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제
    67.
    发明公开
    스네일―ｐ５３ 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제 有权
    SNAIL-p53结合化学抑制剂和药物组合物治疗包含其中的癌性疾病

    公开(公告)号：KR1020120046129A

    公开(公告)日：2012-05-09

    申请号：KR1020120012619

    申请日：2012-02-08

    Applicant: 부산대학교 산학협력단 ,  충남대학교산학협력단

    Inventor： 박범준 ,  하남출 ,  이선혜 ,  송규용 ,  이지현

    IPC: G01N33/574 ,  G01N33/15

    CPC classification number: G01N33/5748 ,  A61K31/10 ,  A61K31/122 ,  C07C317/44 ,  C07C323/52 ,  C07C2602/10

    Abstract: PURPOSE: A compound which suppresses snail-p53 and a therapeutic agent for treating cancer are provided to induce p53 expression in K-ras mutant cell line and to effectively prevent or treat cancer. CONSTITUTION: A method for screening a therapeutic agent for treating K-ras mutagenic cancer comprises: a step of culturing snail and candidate drugs on a p53-fixed plate; a step of selecting a candidate drug which suppresses snail-p53 binding using ELISA reader. The therapeutic agent contains a compound which suppresses snail-p53 binding. A DNA binding domain specifically transfers a drug in K-ras mutant cells.

    Abstract translation: 目的：提供抑制snail-p53的化合物和治疗癌症的治疗剂，以诱导K-ras突变细胞系中的p53表达，并有效预防或治疗癌症。 构成：用于筛选治疗K-ras致突变性癌症的治疗剂的方法包括：在p53固定板上培养蜗牛和候选药物的步骤; 选择使用ELISA读数器抑制snail-p53结合的候选药物的步骤。 治疗剂含有抑制蜗牛p53结合的化合物。 DNA结合域特异性转移K-ras突变体细胞中的药物。

Patent Agency Ranking